Addressing smoking in patients following discharge from Intensive Care
- Disease/Condition
- Smoking
- Study type
- Interventional
- Primary sponsor
- Sir Charles Gairdner and Osborne Park Hospital Group
- Funder
- Sir Charles Gairdner Hospital
- Location
- Australia
- Phase
- Not Applicable
- Start date
- Sep 12, 2022
- End date
- N/A
Self referral to QUIT program assessed by follow-up phone call
Despite a dramatic decline in tobacco smoking prevalence, current smoking rates have plateaued and smoking remains the leading cause of preventable diseases and death in Australia. Smoking rates in ICU patients are higher than the general population, offering an opportunity for intervention, especially as there is good evidence that many smokers do consider cessation following an ICU admission. Thus surviving an ICU admission potentially provides a unique opportunity to promote long-term smoking cessation. Whilst smoking cessation interventions have been evaluated in hospital settings, the optimal intervention remains unclear and no studies looking at combination nicotine replacement therapy (NRT) and counselling have been performed specifically in ICU survivors. Our goal is to conduct a randomized controlled trial comparing standard care (ad hoc advice to patients and NRT) to a formal brief counselling intervention in addition to protocolized NRT. The aim is to improve smoking cessation rates in ICU survivors and thus improve their morbidity and mortality.
- Registry
- Australian New Zealand Clinical Trials Registry
- Trial ID
- ANZCTR12622001205729
- Type
- Non-Device Trial
Access comprehensive clinical trial information for ANZCTR12622001205729 through Pure Global AI's free database. This Not Applicable trial is sponsored by Sir Charles Gairdner and Osborne Park Hospital Group and is currently Not yet recruiting. The study focuses on Smoking.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.